RIG 200 

RIG 200 is an S-nitrosothiol nitric oxide (NO) donor. RIG 200 releases NO through decomposition, activating guanylate cyclase (sGCM) in vascular smooth muscle cells, increasing cGMP levels, and leading to vasodilation. RIG 200 significantly inhibits Collagen (HY-NP003)-induced platelet aggregation in platelet-rich plasma (PRP). RIG 200 may be used in research on coronary artery bypass grafting^[1][2][3].

RIG 200 (4-100 μM) inhibits platelet aggregation induced by Collagen with an IC₅₀ of 0.8 μM in platelet-rich plasma (PRP) but is impossible to inhibit platelet aggregation in whole blood (WB)^[1].
RIG 200 (10 μM) significantly increases the cGMP level of platelets in PRP^[1].
RIG 200 (0.01-10 μM, 30 min) continuously inhibits the contraction effect of isolated vascular rings, and its dilating effect can significantly persist after elution^[2].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

549.55

C₂₁H₃₁N₃O₁₂S

202656-49-3

CC(O[C@@H]1[C@H]([C@@H](O[C@H](COC(C)=O)[C@H]1OC(C)=O)OC(C)=O)NC([C@H](NC(C)=O)C(C)(C)SN=O)=O)=O

Room temperature in continental US; may vary elsewhere.

Please store the product under the recommended conditions in the Certificate of Analysis.

• [1]. Megson IL, et al. Inhibition of human platelet aggregation by a novel S-nitrosothiol is abolished by haemoglobin and red blood cells in vitro: implications for anti-thrombotic therapy. Br J Pharmacol. 2000 Dec;131(7):1391-8.

  [2]. Sogo N, et al. S-nitrosothiols cause prolonged, nitric oxide-mediated relaxation in human saphenous vein and internal mammary artery: therapeutic potential in bypass surgery. Br J Pharmacol. 2000 Nov;131(6):1236-44.

  [3]. Sogo N, et al. A novel S-nitrosothiol (RIG200) causes prolonged relaxation in dorsal hand veins with damaged endothelium. Clin Pharmacol Ther. 2000 Jul;68(1):75-81.  [Content Brief]